Lyme Disease Antibody Testing: Change to Assay

Date: March 20, 2019

Effective Date: April 17, 2019

The URMC Clinical Microbiology Laboratory is instituting a **two tier testing algorithm for Lyme Disease**, replacing the single Lyme C6 antibody currently in use. At this time, the LYME C6 Peptide Antibody (IgG/IgM) will be used and resulted as a **Lyme antibody screening assay.** Specimens which test positive for antibodies to Lyme C6 peptide will then be reflexed to **confirmatory Lyme IgM and IgG ELFA assays.** This constitutes a modified two-tier assay (i.e. a screening EIA followed by a confirmatory EIA/ELFA).

The use of an EIA/ELFA as a second tier improves sensitivity compared to a traditional two tier testing algorithm which used a western blot as a confirmatory second step. The new testing algorithm will be reported as shown below.



Lyme Disease Antibody Testing: Change to Assay

Date: March 20, 2019

Effective Date: April 17, 2019

Testing Information:
Code: LYMAB
SPECIMEN: Serum Separator Tube with 1mL
SCHEDULE: Both tiers will be run Mon-Sat during the day. Expected turn-around-time is 24-72 hours.

Please contact Serology Supervisor, at 275-7801 with any questions.

From: Nicole Pecora MD, PhD
Associate Director, Clinical Microbiology, UR Medicine Labs
University of Rochester Medical Center
Phone: (585) 276-4674
E-mail: Nicole_Pecora@urmc.rochester.edu